January, 2022
Update from Novartis on Planned Trial of Branaplam for Huntington’s Disease
Posted on January 27, 2022
Novartis is developing an experimental HD therapy called branaplam which has the potential to lower huntingtin when taken by mouth. Branaplam…
Read MoreRoche to continue development of tominersen: Community Presentation TODAY
Posted on January 20, 2022
In a community letter released January 18th, Roche announced plans to continue developing the huntingtin-lowering drug tominersen. After analyzing data collected in the Phase III GENERATION HD-1 trial that halted dosing in…
Read MoreResearch Webinar: Roche Joins HDSA to Discuss Latest Data from GENERATION HD-1
Posted on January 13, 2022
One week from today, HDSA will be joined by members of the Roche team at 3:00 PM EST on January 20th for…
Read MoreUpcoming Webinar: New Key Findings from the GENERATION HD-1 Study
Posted on January 6, 2022
Join HDSA at 3:00 PM EST on January 20th for an update from Roche on new findings from the data collected in the GENERATION HD-1 study. This…
Read More